Efficacy and toxicity of therapy immediately after treatment with nivolumab in relapsed multiple myeloma

Leuk Lymphoma. 2018 Jan;59(1):221-224. doi: 10.1080/10428194.2017.1320713. Epub 2017 May 30.
No abstract available

Publication types

  • Clinical Trial, Phase I
  • Letter
  • Multicenter Study

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents, Immunological / adverse effects
  • Antineoplastic Agents, Immunological / therapeutic use
  • Combined Modality Therapy / methods
  • Female
  • Humans
  • Male
  • Middle Aged
  • Multiple Myeloma / drug therapy*
  • Multiple Myeloma / pathology
  • Neoplasm Recurrence, Local
  • Nivolumab / adverse effects
  • Nivolumab / therapeutic use*
  • Remission Induction
  • Treatment Outcome

Substances

  • Antineoplastic Agents, Immunological
  • Nivolumab